About Index Trending news
Analyze
Pricing

Clinical Trials

10–100 Companies
Companies

Growing

53
Funding and Acquisitions

2017 Q2

4 + 0
Curators of Clinical Trials
PE Hub

LabCorp to expand oncology offerings with $1.2 billion Chiltern buy: Reuters

Strategy Health
$10,680,000 Venture capital (Series A)
bizjournals , sec

http://www.bizjournals.com/stlouis/news/2017/06/28/cofactor-raises-10-7-million-from-investors.html?ana=twt

$140,000,000 Private equity
PE Hub

Medical ad firm PatientPoint raises $140 million for digital growth: Reuters

Funding
$3,700,000 Venture capital (Series A)
PE Hub

Lantern Pharma rallies $3.7 mln Series A

Messaging
$6,500,000 Venture capital (Series A)
PE Hub

Circle Pharma racks up about $6.5 mln

Messaging Data leaks
Acquisition
GeekWire

Seattle’s Spiral Genetics acquired by Bay-Area bioinformatics company Omicia

Science
Finextra

Chiltern railways to trial ticket-free travel

$4,500,000 Venture capital (Series A)
Added by
via FinSMEs

Circle Pharma Raises over $4.5M in Series A Funding

$16,500,000 Venture capital
FinSMEs , prnewswire

MedNet Solutions Raises $16.5m in Second Funding

Funding
Acquisition
Added by
via mna , foxwilmington , yourohiovalley

Mergers & Acquisitions - PatientPoint, acquired MedCenterDisplay

$1,500,000 Seed fund
Added by
via FinSMEs

Intent Solutions Raises $1.5M In Seed Funding

Finextra

Chiltern Railways to test smartphone detection payment system

Seed fund
FinSMEs

Healthcare Company Abreos Biosciences Raises Seed Funding Round

The Motley Fool

The $100 Million Platform Intrexon Investors Forgot

The Motley Fool

Why Intrexon Won't Commercialize Fuels by 2018

The Motley Fool

Better Buy: Intrexon Corporation vs. Inovio Pharmaceuticals Inc.

The Motley Fool

Intrexon Battles Thermodynamics, but Thermodynamics Always Wins

The Motley Fool

Intrexon vs. MosquitoMate: Who Has the Better Zika Tool?

$23,000,000 Venture capital (Series B)
businesswire , FinSMEs

Omicia Raises $23 Million in Series B Funding | Business Wire

The Motley Fool

Here's Why Intrexon Corporation Was All the Buzz in May

Health Science